Screen Fatigue at a Desk: Does Omega-3 Do Anything?

Your blink rate falls by two-thirds at a screen

Tsubota and Nakamori put 104 healthy office workers through three conditions and counted. Relaxed, they blinked 22 times a minute. Reading a book flat on the desk, 10. Looking at text on a screen, 7.

That is the mechanism, in one line. Every blink resurfaces the tear film. Blink a third as often and the film sits there evaporating between wipes.

The letter ran in the New England Journal of Medicine in 1993, on monitors that would look absurd now. Nothing about the finding has aged. If anything the exposure has got worse, because the screen is no longer only on the desk.

Screen height compounds it. A monitor above eye level makes you look up, which opens the lid aperture and exposes more surface. Drop the screen so you look slightly down at it. That costs nothing and it is the single change with the clearest mechanical logic behind it.

Two different problems share one name

"Screen fatigue" covers two things that behave differently.

The first is focusing strain. Your ciliary muscle holds a near focus for hours, your eyes converge, and you get headache, brow ache and blur that clears when you look up. An optometrist fixes this with a prescription, not a capsule.

The second is the ocular surface. Grit, burning, watering, a gummy feeling by four in the afternoon. That is tear film, and it is the only half of the problem omega-3 could plausibly touch.

Worth knowing before you spend anything: if your symptom is a headache behind the eyes, no fish oil on earth is aimed at it.

How common is the whole cluster? Anbesu and Lema pooled 45 cross-sectional studies covering 17,526 people and reported 66%. Treat that number with suspicion. Heterogeneity was 99.4%, and the individual studies ranged from 12% in Japan to 99% in Pakistan. It tells you this is common. It does not tell you your odds.

The largest trial found nothing

DREAM is the trial everything else gets measured against. It enrolled 535 adults with moderate-to-severe dry eye, mean age 58, and ran for a full year. One arm took 2,000 mg EPA plus 1,000 mg DHA daily. The other took 5,000 mg of refined olive oil.

Both groups improved. Neither group improved more than the other.

Two honest caveats. DREAM recruited people with diagnosed dry eye, not office workers with screen symptoms. And the comparator was olive oil, which is not obviously inert.

Neither caveat rescues the result. This was the biggest, longest and best-controlled trial in the field, and it landed on nothing.

The screen-user trials say the opposite, loudly

Bhargava and colleagues ran the only large trials aimed specifically at screen workers. In 2015 they randomised 478 people who had used computers for more than three hours a day for at least a year. At the end, 70% of the omega-3 group reported being completely symptom-free, against 14.9% on placebo.

A follow-up in 2016 randomised 522 visual display terminal users to 2,400 mg a day or olive oil for 45 days, with tear break-up time and conjunctival cytology as endpoints.

Now read that sceptically. A 70% versus 15% split is enormous. Effect sizes that size almost never survive replication in nutrition research, and nothing in the later literature has come close to reproducing it. Both trials came from one research group, in one country, and both predate DREAM.

The size of the sample is not the same thing as the strength of the evidence. Use the Bhargava numbers as a reason to try it, not as your expected outcome. We have written more on why big-sounding supplement trials keep shrinking.

Pooled, the signs move and the symptoms barely do

Cochrane reviewed 34 randomised trials across 13 countries, covering more than 4,314 participants. Their split is the most useful summary anyone has produced.

Omega-3 on its own had little to no effect on dry eye symptoms, rated low certainty. It did improve tear production on the Schirmer test, at moderate certainty, and tear osmolarity at low certainty. Symptoms improved when omega-3 was added on top of artificial tears or warm compresses, rather than used alone.

That is a real distinction. Your eye can measurably produce more tears while you feel exactly the same.

Wang and Ko pooled 19 trials and 4,246 patients in 2023 and reported a large symptom effect, Hedges' g of −1.047. Their own paper flags the heterogeneity behind it, and the positive weight comes largely from the small trials. Their meta-regression found the EPA percentage of the dose predicted symptom reduction, with a coefficient of −0.0154.

The newest properly controlled trial went the way DREAM did. Eom and colleagues gave 132 patients 1,680 mg EPA plus 560 mg DHA or grape-seed oil for 12 weeks. Scores fell 22.7 points on omega-3 and 18.8 on the control. The 3.9-point difference had a confidence interval from −10.9 to 3.1 and a p-value of 0.28.

The pattern across two decades is consistent. The bigger and tighter the trial, the smaller the effect.

Dose, form, and how long to give it

If you are going to try it, three things follow from the evidence above.

Go EPA-dominant. Every trial that reported a symptom benefit used an EPA-heavy oil, and the Wang and Ko meta-regression points the same way. This is where we have to be straight with you: our own algae softgel is DHA at 500 mg with no meaningful EPA. It was formulated for structural needs, brain and retina, and it has not been tested for tear film. If your only goal is the ocular surface, an EPA-dominant oil has more behind it than ours does. The difference between the two fatty acids is not cosmetic.

Use a real dose. The trials used 1,000 to 3,000 mg of combined EPA and DHA daily. The 250 mg of DHA behind the GB authorised claim for maintaining normal vision is a different thing entirely, and that claim says nothing about screens or symptoms.

Give it twelve weeks. Reported changes in these trials appeared between 30 and 90 days. If nothing has moved by three months, stop paying for it.

Diet is the cheaper version of the same intervention. UK adults aged 19 to 64 average 56 g of oily fish a week against a 140 g recommendation. Two tins of sardines gets you most of the way there. Our guide to what a daily DHA target should look like covers the arithmetic.

What actually shifts the symptoms

Blink properly and on purpose. Full closures, not flutters. Most people at a screen blink incompletely, which spreads nothing across the lower third of the cornea.

Take breaks away from the screen. Talens-Estarelles and colleagues put break-reminder software on 35 people's computers for two weeks. Symptom scores improved on three separate dry eye questionnaires. The binocular measures — acuity, stereopsis, vergence, near point of convergence — did not budge. It was small and uncontrolled, so weigh it accordingly. It is also free.

Look at your air, not just your screen. Air conditioning, car vents and a hot office all raise evaporation. Moving your chair out of the airflow is a bigger lever than most supplements.

Get your eyes tested. If you are over 45 and your symptom is ache and blur rather than grit, uncorrected presbyopia is the more likely cause. That is an optometrist appointment, not a purchase.

Preservative-free artificial tears are cheap, work by the obvious mechanism, and have far better evidence than any oral supplement here. If symptoms persist or one eye is affected more than the other, see an optometrist or your GP.

What I would actually do

Start with the free things, because the evidence for them is no worse and they cost nothing. Drop the monitor. Move out of the draught. Blink fully. Book an eye test you have been putting off.

Then, if you still want to try omega-3, buy an EPA-dominant oil at 1,000 mg or more of combined EPA and DHA, run it for twelve weeks, and judge it honestly at the end.

And keep the two reasons separate in your head. The tear film case for omega-3 is weak, and the largest trial in the field is null. The dietary case for getting enough long-chain omega-3 is a different argument with a different evidence base. Buying for the second reason is defensible. Buying for the first, at this point, is optimism.

References

1. Tsubota, K. & Nakamori, K. (1993). "Dry Eyes and Video Display Terminals." New England Journal of Medicine, 328(8), 584. PMID 8426634.
2. Asbell, P.A., Maguire, M.G., Pistilli, M., et al. (2018). "n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease." New England Journal of Medicine, 378(18), 1681-1690. DOI 10.1056/NEJMoa1709691.
3. Downie, L.E., Ng, S.M., Lindsley, K.B. & Akpek, E.K. (2019). "Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease." Cochrane Database of Systematic Reviews, CD011016.pub2. DOI 10.1002/14651858.CD011016.pub2.
4. Wang, W.-X. & Ko, M.-L. (2023). "Efficacy of Omega-3 Intake in Managing Dry Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Journal of Clinical Medicine, 12(22), 7026. DOI 10.3390/jcm12227026.
5. Eom, Y., Jun, I., Jeon, H.S., et al. (2024). "Re-Esterified Triglyceride Omega-3 Fatty Acids in Dry Eye Disease With Meibomian Gland Dysfunction: A Randomized Clinical Trial." JAMA Ophthalmology, 142(7), 617. DOI 10.1001/jamaophthalmol.2024.1482.
6. Saldanha, I.J. (2024). "Omega-3 Fatty Acid Supplements May Not Improve Dry Eye Symptoms." JAMA Ophthalmology, 142(7), 625. DOI 10.1001/jamaophthalmol.2024.1658.
7. Bhargava, R., Kumar, P., Phogat, H., Kaur, A. & Kumar, M. (2015). "Oral omega-3 fatty acids treatment in computer vision syndrome related dry eye." Contact Lens and Anterior Eye, 38(3), 206-210. DOI 10.1016/j.clae.2015.01.007.
8. Bhargava, R. & Kumar, P. (2016). "Short-Term Omega 3 Fatty Acids Treatment for Dry Eye in Young and Middle-Aged Visual Display Terminal Users." Eye & Contact Lens, 42(4), 231-236. DOI 10.1097/ICL.0000000000000179.
9. O'Byrne, C. & O'Keeffe, M. (2023). "Omega-3 fatty acids in the management of dry eye disease - an updated systematic review and meta-analysis." Acta Ophthalmologica. DOI 10.1111/aos.15255.
10. Anbesu, E.W. & Lema, A.K. (2023). "Prevalence of computer vision syndrome: a systematic review and meta-analysis." Scientific Reports, 13, 1801. DOI 10.1038/s41598-023-28750-6.
11. Talens-Estarelles, C., Garcia-Marques, J.V., Cervino, A. & Garcia-Lazaro, S. (2023). "The effects of breaks on digital eye strain, dry eye and binocular vision: Testing the 20-20-20 rule." Contact Lens and Anterior Eye. DOI 10.1016/j.clae.2022.101744.
12. Public Health England (2020). "NDNS: results from years 9 to 11 (combined) - statistical summary." GOV.UK.

Algae DHA, 500 mg a serving

Our softgel is DHA-dominant and built for structural needs — brain and retina — rather than tear film. It is cold-pressed algae oil, so no fish, no ocean contaminants, and 500 mg of DHA per daily serving.

Shop Omega-3 DHA →